{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:12:58Z","timestamp":1792141978491,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40258-020-00624-2","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T11:04:00Z","timestamp":1613127840000},"page":"501-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Costs of Illness of Spinal Muscular Atrophy: A Systematic Review"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-7151","authenticated-orcid":false,"given":"Erik","family":"Landfeldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Pechmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"Lochm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sejersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"issue":"7","key":"624_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Leary R, McMacken G, Konig K, Kirschner J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264(7):1465\u201373. https:\/\/doi.org\/10.1007\/s00415-017-8549-1.","journal-title":"J Neurol."},{"issue":"12","key":"624_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/sj.ejhg.5201288","volume":"12","author":"S Ogino","year":"2004","unstructured":"Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12(12):1015\u201323. https:\/\/doi.org\/10.1038\/sj.ejhg.5201288.","journal-title":"Eur J Hum Genet."},{"issue":"1","key":"624_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy: a literature review. Orphanet J Rare Dis. 2017;12(1):124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","journal-title":"Orphanet J Rare Dis."},{"issue":"9","key":"624_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/wnl.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000000741.","journal-title":"Neurology."},{"issue":"6","key":"624_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391. https:\/\/doi.org\/10.1002\/ana.25101.","journal-title":"Ann Neurol."},{"issue":"9630","key":"624_CR6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(08)60921-6 ((PMID: 18572081)).","journal-title":"Lancet"},{"issue":"1","key":"624_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/jnd-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy: new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313. https:\/\/doi.org\/10.3233\/jnd-190424.","journal-title":"J Neuromuscul Dis."},{"issue":"10","key":"624_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005.","journal-title":"J Clin Epidemiol."},{"issue":"1","key":"624_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40258-018-0418-2","volume":"17","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Zethraeus N, Lindgren P. Standardized questionnaire for the measurement, valuation, and estimation of costs of informal care based on the opportunity cost and proxy good method. Appl Health Econ Health Policy. 2019;17(1):15\u201324. https:\/\/doi.org\/10.1007\/s40258-018-0418-2.","journal-title":"Appl Health Econ Health Policy."},{"issue":"4","key":"624_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1017\/S0266462300008254","volume":"10","author":"M Johannesson","year":"1994","unstructured":"Johannesson M. The concept of cost in the economic evaluation of health care: a theoretical inquiry. Int J Technol Assess Health Care. 1994;10(4):675\u201382.","journal-title":"Int J Technol Assess Health Care."},{"key":"624_CR11","unstructured":"Wells G, Shea B, O\u2019Connell J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 2019. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 10 Oct 2019."},{"key":"624_CR12","unstructured":"World Health Organization. International classification of diseases for mortality and morbidity statistics. 10th Revision. 2020. https:\/\/icd.who.int\/browse10\/2019\/en. Accessed 30 Sep 2020."},{"issue":"1","key":"624_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-017-0695-0","volume":"12","author":"J Lopez-Bastida","year":"2017","unstructured":"Lopez-Bastida J, Pena-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):141. https:\/\/doi.org\/10.1186\/s13023-017-0695-0.","journal-title":"Orphanet J Rare Dis."},{"key":"624_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2018.11.002","volume":"92","author":"M Lee Jr","year":"2019","unstructured":"Lee M Jr, Franca UL, Graham RJ, McManus ML. Pre-nusinersen hospitalization costs of children with spinal muscular atrophy. Pediatr Neurol. 2019;92:3\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2018.11.002.","journal-title":"Pediatr Neurol."},{"issue":"11","key":"624_CR15","doi-asserted-by":"publisher","first-page":"e031271","DOI":"10.1136\/bmjopen-2019-031271","volume":"9","author":"J Darba","year":"2019","unstructured":"Darba J, Marsa A. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis. BMJ Open. 2019;9(11):e031271. https:\/\/doi.org\/10.1136\/bmjopen-2019-031271.","journal-title":"BMJ Open."},{"issue":"2","key":"624_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s41669-018-0093-0","volume":"3","author":"J Cardenas","year":"2019","unstructured":"Cardenas J, Menier M, Heitzer MD, Sproule DM. High healthcare resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1 (SMA1): retrospective analysis of the Kid\u2019s Inpatient Database (KID). Pharmacoecon Open. 2019;3(2):205\u201313. https:\/\/doi.org\/10.1007\/s41669-018-0093-0.","journal-title":"Pharmacoecon Open."},{"key":"624_CR17","doi-asserted-by":"publisher","first-page":"A71","DOI":"10.1136\/archdischild-2019-rcpch.171","volume":"104","author":"I Ali","year":"2019","unstructured":"Ali I, Gilchrist F, Carroll WD, Alexander J, Clayton S, Willis T, et al. Healthcare utilisation in SMA type 1 patients treated with nusinersen. Arch Dis Child. 2019;104:A71\u20132. https:\/\/doi.org\/10.1136\/archdischild-2019-rcpch.171.","journal-title":"Arch Dis Child."},{"issue":"1","key":"624_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):73\u20139. https:\/\/doi.org\/10.1080\/13696998.2019.1646263.","journal-title":"J Med Econ."},{"issue":"8","key":"624_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","volume":"19","author":"EP Armstrong","year":"2016","unstructured":"Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822\u20136. https:\/\/doi.org\/10.1080\/13696998.2016.1198355.","journal-title":"J Med Econ."},{"issue":"1","key":"624_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","volume":"1","author":"C Klug","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;1(1):58. https:\/\/doi.org\/10.1186\/s13023-016-0424-0.","journal-title":"Orphanet J Rare Dis."},{"issue":"3","key":"624_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.36469\/63185","volume":"6","author":"H Tan","year":"2019","unstructured":"Tan H, Gu T, Chen E, Punekar R, Shieh PB. Healthcare utilization, costs of care, and mortality among patients with spinal muscular atrophy. J Health Econ Outcomes Res. 2019;6(3):185\u201395. https:\/\/doi.org\/10.36469\/63185.","journal-title":"J Health Econ Outcomes Res."},{"key":"624_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/2284240319867662","author":"A Marcellusi","year":"2019","unstructured":"Marcellusi A, Bini C, Casiraghi J, D\u2019Ambrosio F, Rotundo MA, et al. Cost of illness of spinal muscular atrophy (SMA) in Italy. Glob Reg Health Technol Assess. 2019. https:\/\/doi.org\/10.1177\/2284240319867662.","journal-title":"Glob Reg Health Technol Assess."},{"issue":"6","key":"624_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","volume":"37","author":"S Zuluaga-Sanchez","year":"2019","unstructured":"Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, et al. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019;37(6):845\u201365. https:\/\/doi.org\/10.1007\/s40273-019-00769-6.","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"624_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40261-020-00897-4","volume":"40","author":"J Darba","year":"2020","unstructured":"Darba J. Direct medical costs of spinal muscular atrophy in the Catalonia region: a population-based analysis. Clin Drug Invest. 2020;40(4):335\u201341. https:\/\/doi.org\/10.1007\/s40261-020-00897-4.","journal-title":"Clin Drug Invest."},{"issue":"1","key":"624_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000009715","volume":"95","author":"GM Chambers","year":"2020","unstructured":"Chambers GM, Settumba SN, Carey KA, Cairns A, Menezes MP, Ryan M, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. 2020;95(1):e1-10. https:\/\/doi.org\/10.1212\/WNL.0000000000009715 ((Epub 2020 Jun 8 PMID: 32513788)).","journal-title":"Neurology."},{"issue":"16","key":"624_CR26","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.3390\/ijerph17165640.PMID:32764338;PMCID:PMC7459726","volume":"17","author":"LM Pe\u00f1a-Longobardo","year":"2020","unstructured":"Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano E, et al. The economic impact and health-related quality of life of spinal muscular atrophy: an analysis across Europe. Int J Environ Res Public Health. 2020;17(16):5640. https:\/\/doi.org\/10.3390\/ijerph17165640.PMID:32764338;PMCID:PMC7459726.","journal-title":"Int J Environ Res Public Health."},{"issue":"1","key":"624_CR27","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Market Access Health Policy. 2019;7(1):1601484. https:\/\/doi.org\/10.1080\/20016689.2019.1601484.","journal-title":"J Market Access Health Policy."},{"key":"624_CR28","unstructured":"Morningstar, Inc. 2019. https:\/\/www.morningstar.com. Accessed 29 Nov 2019."},{"issue":"6","key":"624_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/wnl.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336. https:\/\/doi.org\/10.1212\/wnl.0000000000000669.","journal-title":"Neurology."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-020-00624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-020-00624-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-020-00624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T01:10:30Z","timestamp":1625879430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-020-00624-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s40258-020-00624-2","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"18 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Karolinska Institute. No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Erik Landfeldt is an employee of ICON plc (Stockholm, Sweden), outside the submitted work. Astrid Pechmann reports receiving compensation for presentations and training activities from Biogen, and research funding from Biogen and AveXis, outside the submitted work. Thomas Sejersen reports receiving honoraria for lectures and participation in advisory board meetings from Biogen, AveXis, and Roche, outside the submitted work. Hugh J. McMillan has participated in an advisory board for AveXis, and reports research funding from Roche, outside the submitted work. Hanns Lochm\u00fcller has no conflicts of interest that are directly relevant to the content of this article","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data analyzed as part of this study are included in this published article (and its supplementary information files).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Erik Landfeldt conceptualized and designed the study, conducted the literature review and the analysis, led the interpretation of findings, drafted the manuscript, critically reviewed the manuscript for important intellectual content, and approved the final manuscript version as submitted. Astrid Pechmann conducted the literature review, interpreted the findings, critically reviewed the manuscript for important intellectual content, and approved the final manuscript version as submitted. Hugh J. McMillan interpreted the findings, critically reviewed the manuscript for important intellectual content, and approved the final manuscript version as submitted. Hanns Lochm\u00fcller interpreted the findings, critically reviewed the manuscript for important intellectual content, and approved the final manuscript version as submitted. Thomas Sejersen conceptualized and designed the study, interpreted the findings, critically reviewed the manuscript for important intellectual content, and approved the final manuscript version as submitted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}